CIMG Inc. Enters into Agreement to Acquire Daren Business Technology Limited, Expanding into the Biopharmaceutical Industry
MWN-AI** Summary
CIMG Inc. has announced a significant move to expand its operations into the biopharmaceutical sector by entering a definitive share purchase agreement to acquire Daren Business Technology Limited. The transaction, executed by CIMG's subsidiary DZR Tech Limited, involves purchasing 100% of Daren’s equity for approximately $40 million, paid through shares held in escrow. This acquisition reflects CIMG's strategic diversification into one of the fastest-growing industries globally.
The acquisition is contingent upon customary closing conditions and is expected to finalize within 30 days. Notably, the release of the escrowed shares will occur in four phases over a 3.5-year assessment period, starting in April 2026. Each phase, which corresponds to specific performance targets for Daren, will involve achieving audited revenue milestones: $29 million for the first phase, escalating to $257 million by the final phase.
Daren Business Technology operates as a high-tech enterprise focused on biomedicine, emphasizing innovation and technological solutions to enhance human well-being. With a strong track record in R&D, quality control, and supply chain management, Daren aims to provide healthcare solutions tailored to its target markets.
Alice Wang, CIMG's Chairwoman and CEO, articulated the strategic vision behind the acquisition, highlighting the importance of integrating technological innovations to establish a new growth engine for the company. She underscored the potential of the biopharmaceutical industry as a critical sector for future growth.
CIMG Inc. specializes in digital health and sales development, utilizing advanced technologies, including AI and cryptocurrencies, to bolster its business offerings. The company serves a variety of clients across industries, positioning itself for continued growth and innovation. This acquisition is a pivotal step in reinforcing CIMG’s market presence, aiming for sustained profitability in the burgeoning biopharmaceutical landscape.
MWN-AI** Analysis
CIMG Inc.'s recent announcement regarding its acquisition of Daren Business Technology Limited represents a strategic pivot into the biopharmaceutical sector, which is poised for significant growth. This acquisition aligns with CIMG's diversification strategy and could offer substantial synergies, particularly given Daren's strong footing in biomedical R&D and quality control.
Investors should closely assess CIMG's performance targets linked to the acquisition, which demand aggressive revenue growth metrics, starting from $29 million in the first year to an ambitious $257 million by the end of the assessment period. While these targets reflect confidence in Daren’s capabilities, they constitute a high-risk profile for CIMG, as failure to meet these benchmarks could lead to a reduction in the escrowed shares being released, directly affecting both shareholder value and market perception.
The biopharmaceutical market is increasingly competitive, with regulatory challenges and rapid technological advancements dictating success. CIMG's integration of AI and innovation in healthcare can provide a competitive edge; however, the execution of this integration will be crucial. It's worth noting that CIMG has a history in digital health, which can also complement its new venture, but investors must watch for operational challenges in tackling this new sector.
From an investment standpoint, CIMG's stock may experience volatility as the market reacts to the acquisition's success or setbacks. Short-term speculators might find opportunities in this volatility, while long-term investors should prepare for potential fluctuations driven by performance metrics.
Overall, due diligence is vital. Investors should monitor CIMG's progress post-acquisition, market dynamics in the biopharmaceutical field, and long-term financial health to make informed investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
HONG KONG, Feb. 10, 2026 /PRNewswire/ -- CIMG Inc. ("CIMG" or the "Company") (Nasdaq: IMG), a business group specializing in digital health and sales development, which utilizes technologies and marketing networks to enhance its business partners' sales growth and commercial value, today announced that its wholly owned subsidiary, DZR Tech Limited ("DZR"), entered into a definitive share purchase agreement on February 5, 2026 (the "Agreement") with the sole shareholder of Daren Business Technology Limited ("Daren" or the "Target Company") to acquire 100% of the issued and outstanding equity interests in Daren. The transaction is subject to the completion of customary closing conditions, including the satisfactory completion of due diligence. The Company expects the parties to complete the closing within 30 days following the execution of the Agreement.
Under the Agreement, the aggregate purchase consideration will be paid in the form of shares of the Company held in escrow, with an aggregate value of approximately $40 million. These escrowed shares will be released in four phases over approximately 3.5-year assessment period from April 2026 through September 2029, based on the Target Company's achievement of specified performance targets. The release ratios for each phase are set at 6%, 14%, 28%, and 52%, respectively.
Performance Targets are as follows:
April 1, 2026 – September 30, 2026: the Target Company shall achieve audited revenue of no less than $29 million;
October 1, 2026 – September 30, 2027: the Target Company shall achieve audited revenue of no less than $71 million;
October 1, 2027 – September 30, 2028: the Target Company shall achieve audited revenue of no less than $143 million;
October 1, 2028 – September 30, 2029: the Target Company shall achieve audited revenue of no less than $257 million.
The value and number of escrowed shares subject to release are subject to adjustment in accordance with the terms of the Agreement. If the applicable performance targets are not achieved for any assessment period, the portion of the escrowed shares allocated to such period will be reduced in accordance with the Agreement and the unreleased shares will be canceled. If the cumulative performance targets are exceeded, such excess performance may be applied to offset any shortfalls from prior assessment periods.
Daren is a high-tech enterprise with the core mission of "Empowering life and health through innovation, safeguarding human well-being with technology." It integrates R&D, production, marketing and technical services of biomedicine into a comprehensive whole. Since its incorporation, Daren has focused on biomedicine and has developed capabilities in R&D, quality control and supply chain management. It aims to provide medical products and related solutions to patients in its target markets.
Alice Wang, Chairwoman and Chief Executive Officer of CIMG, stated: "The biopharmaceutical industry is one of the world's fastest-growing core sectors. This acquisition marks a key step in our group's diversification strategy. Moving forward, we will continue to increase investment in this field, leveraging technological integration and model innovation to build a new growth engine for the Company."
About CIMG
CIMG is a business group specializing in digital health and sales development, with a cryptocurrency-focused strategy. The Company leverages AI and cryptocurrencies (such as Bitcoin and stablecoins) to drive business growth, helping clients maximize user growth and enhance brand management value. The Company's current client portfolio includes brands such as Kangduoyuan, Maca-Noni, Qianmao, Huomao, and Coco-mango.
Forward-Looking Statements
This press release contains information about the Company's view of its future expectations, plans and prospects that constitute forward-looking statements. Actual results may differ materially from historical results or those indicated by these forward-looking statements as a result of a variety of factors including, but not limited to, risks related to the execution, timing, and realization of the proposed acquisition and related transactions, risks and uncertainties associated with its ability to raise additional funding, its ability to maintain and grow its business, variability of operating results, its ability to maintain and enhance its brand, its development and introduction of new products and services, the successful integration of acquired companies, technologies and assets into its portfolio of products and services, marketing and other business development initiatives, competition in the industry, general government regulation, economic conditions, dependence on key personnel, the ability to attract, hire and retain personnel who possess the technical skills and experience necessary for its operations, and its ability to protect its intellectual property. The Company encourages you to review other factors that may affect its future results in its Annual Reports, Quarterly Reports, registration statements, and other filings with the Securities and Exchange Commission.
SOURCE CIMG Inc.
FAQ**
How does CIMG Inc. IMG plan to integrate Daren Business Technology Limited's biopharmaceutical capabilities into its existing digital health and sales development model post-acquisition?
What specific performance targets must Daren Business Technology Limited achieve for CIMG Inc. IMG to fully release the escrowed shares over the 3.5-year assessment period?
Given the $40 million purchase consideration in shares and the set performance targets, what strategies does CIMG Inc. IMG have to ensure Daren meets these revenue targets?
How does CIMG Inc. IMG foresee the acquisition of Daren Business Technology Limited contributing to its long-term growth in the biopharmaceutical sector amid increasing competition in the industry?
**MWN-AI FAQ is based on asking OpenAI questions about CIMG Inc. (NASDAQ: IMG).
NASDAQ: IMG
IMG Trading
-23.18% G/L:
$0.3789 Last:
845,219 Volume:
$0.492 Open:
